metronidazole oral
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
507
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
March 25, 2026
First-in-Human Randomized Controlled Pilot Trial of a Maxillofacial Drug Delivery Platform for Low-Dose Systemic Delivery.
(PubMed, Cureus)
- "Methods In this parallel-group, pilot RCT (n = 20), patients undergoing maxillary first molar endodontic therapy received either 400 mg of oral metronidazole (control group; n = 10) or 5 mg of metronidazole administered using the maxillofacial platform (study group; n = 10)...No local or systemic AEs were observed in either group. Conclusion The maxillofacial drug delivery platform demonstrates potential for safe and rapid systemic drug delivery at low doses."
First-in-human • Journal • P1 data
March 24, 2026
The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study
(clinicaltrials.gov)
- P=N/A | N=114 | Not yet recruiting | Sponsor: Guy's and St Thomas' NHS Foundation Trust | Trial completion date: Jun 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2027
Trial completion date • Trial primary completion date • Vaginitis
March 23, 2026
CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease
(clinicaltrials.gov)
- P1 | N=100 | Active, not recruiting | Sponsor: The Cleveland Clinic | Trial completion date: Dec 2026 ➔ Dec 2029 | Trial primary completion date: Dec 2025 ➔ Dec 2027
Trial completion date • Trial primary completion date • Cardiovascular
February 04, 2026
Bioavailability of oral metronidazole: promotion of oral vs IV initiative
(ESCMID Global 2026)
- No abstract available
March 06, 2026
Hematogenous Fusobacterium Infection Presenting as Multifocal Brain Abscesses Without Contiguous Source
(AAN 2026)
- "Head CT revealed multiple right-hemispheric lesions with vasogenic edema and 4 mm midline shift; MRI demonstrated multiple ring-enhancing supratentorial abscesses, largest in the right parietal and parieto-occipital regions.He received empiric vancomycin, cefepime, and metronidazole, followed by right parietal craniotomy with evacuation of purulent material; cultures remained sterile...Diagnostic studies were negative for co-infection, including HIV, and showed no evidence of immunocompromise.He was discharged at his neurologic baseline with symptom resolution, on a three-week course of IV ceftriaxone and oral metronidazole, with outpatient follow-up. This case describes a rare hematogenous Fusobacterium infection in an immunocompetent patient, presenting with multifocal brain abscesses and no contiguous source. The absence of typical predisposing factors, including head or neck infection, trauma, or instrumentation, makes this presentation particularly uncommon."
Cardiovascular • CNS Disorders • Epilepsy • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Otorhinolaryngology
February 26, 2026
Pharmacokinetic analysis and steady-state predictions of different preparations of metronidazole administered per rectum in adult horses.
(PubMed, J Vet Intern Med)
- "With the tested preparations, rectal administration of metronidazole at a standard dosage of 20 mg/kg yielded subtherapeutic plasma concentrations. Administering a 4-fold higher dose rectally in water might overcome these limitations. Oral and intravenous routes remain the preferred methods for administering metronidazole in horses."
Journal • PK/PD data
February 25, 2026
Fulminant Clostridioides difficile Infection During Repeated High-Dose Cytarabine Consolidation for Acute Myeloid Leukemia: A Fatal Case.
(PubMed, Cureus)
- "The initial episode was mild diarrhea during myelosuppression and was managed by oral metronidazole. This case illustrates the unpredictable severity of recurrent CDI during intensive chemotherapy. It highlights the critical importance of guideline-adherent antimicrobial therapy, particularly the use of fidaxomicin or vancomycin rather than metronidazole in high-risk patients."
Journal • Acute Myelogenous Leukemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Metabolic Disorders • Neutropenia • Oncology • Pain • Septic Shock
February 25, 2026
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
(clinicaltrials.gov)
- P2 | N=33 | Active, not recruiting | Sponsor: Jing-yuan Fang, MD, Ph. D | Recruiting ➔ Active, not recruiting | N=25 ➔ 33 | Trial primary completion date: Dec 2025 ➔ Dec 2026
Enrollment change • Enrollment closed • Mismatch repair • pMMR • Trial primary completion date • Colorectal Cancer • Hepatology • Oncology • Solid Tumor
February 04, 2026
CONCURRENT CLOSTRIDIUM DIFFICILE COLITIS AND CYTOMEGALOVIRUS INFECTION AS A CAUSE OF PERSISTENT DIARRHEA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMA FOLLOWING BENDAMUSTINE-BASED CONDITIONING.
(PubMed, Acta Clin Croat)
- "After treatment with oral metronidazole, vancomycin and fidaxomicin, diarrhea persisted despite undetectable C. difficile toxin, with elevation of hepatic enzymes. Eventually, CMV infection was diagnosed by real-time polymerase chain reaction and treated with ganciclovir and valganciclovir...Bendamustine-induced colitis and prior rituximab treatment may have been additional risk factors in this patient. Therefore, more comprehensive workup of diarrhea is needed in ASCT recipients treated with these agents."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Transplantation
January 24, 2026
METABOLIC ACTIVITY OF CERVICAL IMMUNE CELLS DECREASES AFTER SUCCESSFUL TREATMENT OF BACTERIAL VAGINOSIS
(WRMC 2026)
- "Cervical biopsy samples were collected from women before vs after successful treatment of BV with a standard course of oral metronidazole... This increase in puromycin incorporation indicates increased translation and activation of CD4+ and CD8+ in the presence of BV. Despite limited sample size, consistent increases in CD4+ and CD8+ cell metabolism during BV infection indicates that BV metabolically influences cervical immune cells and this effect can be reversed by successful BV treatment. This finding suggests a unique mechanism by which BV may increase HIV susceptibility and may inform novel therapeutics for BV."
Immune cell • Cervical Cancer • Gynecology • Human Immunodeficiency Virus • Infectious Disease • Vaginitis • CD4 • CD8
February 10, 2026
Letter to the Editor: Topical versus oral metronidazole for post-haemorrhoidectomy pain: A systematic review and meta-analysis of randomized controlled trials.
(PubMed, Colorectal Dis)
- No abstract available
Journal • Retrospective data • Pain
February 02, 2026
Anaerobic pericarditis due to Clostridium ramosum: First known case report.
(PubMed, IDCases)
- "He was treated with intravenous ampicillin-sulbactam followed by oral metronidazole, with resolution of the effusion and no recurrence on follow-up. Importantly, routine anaerobic cultures of pericardial fluid should be considered to avoid missed diagnoses. Recognition of rare anaerobic pathogens in pericardial infections expands the understanding of their pathogenic potential and informs future diagnostic and therapeutic approaches."
Journal • Atrial Fibrillation • Cardiovascular • CNS Disorders • Depression • Dyslipidemia • Hematological Disorders • Hypertension • Infectious Disease • Psychiatry • Septic Shock
February 01, 2026
REaCT-NSQIP: Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery
(clinicaltrials.gov)
- P4 | N=630 | Active, not recruiting | Sponsor: Ottawa Hospital Research Institute | Recruiting ➔ Active, not recruiting
Enrollment closed
January 13, 2026
Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
(clinicaltrials.gov)
- P=N/A | N=166 | Completed | Sponsor: HaEmek Medical Center, Israel | N=750 ➔ 166 | Trial completion date: Aug 2025 ➔ Dec 2025 | Recruiting ➔ Completed
Enrollment change • Trial completion • Trial completion date
January 13, 2026
From the Ear to the Brain: Otitis Externa Complicated by Coalescent Mastoiditis Leading to Temporal Lobe Abscess and Wernicke's Aphasia.
(PubMed, Cureus)
- "Given the small size of the abscess and absence of mass effect, she was managed nonoperatively with intravenous cefepime and vancomycin and oral metronidazole, alongside intensive glycemic optimization. She completed a six-week antimicrobial regimen and achieved full neurological recovery with near-complete radiographic resolution. This case highlights that inadequately treated otitis externa may serve as a suspected otogenic source of intracranial abscess in patients with uncontrolled diabetes and emphasizes the importance of early MRI evaluation when neurologic symptoms arise, even when CT imaging and laboratory findings are initially reassuring."
Journal • Cardiovascular • CNS Disorders • Dermatology • Diabetes • Infectious Disease • Metabolic Disorders • Otorhinolaryngology • Type 2 Diabetes Mellitus
December 24, 2025
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
(clinicaltrials.gov)
- P2 | N=15 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027
dMMR • Trial completion date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Small Intestinal Carcinoma • Solid Tumor • Transplantation • CEACAM5 • MLH1 • MSH2 • MSH6 • MSI
December 15, 2025
Physicochemical, compressional, mechanical, and dissolution properties of metronidazole tablets prepared with cocoa pod gum.
(PubMed, Polim Med)
- "Cocoa pod gum exhibits promising binder properties comparable to XNG and may serve as a cost-effective, sustainable and biocompatible alternative to conventional excipients in tablet formulations."
Journal
December 10, 2025
Revisiting the Disulfiram-Like Reaction Between Alcohol and Oral Metronidazole.
(PubMed, Sex Transm Dis)
- "While all four case reports and one older clinical trial reported a potential link between some oral 5-nitroimidazoles and DLR, 3 clinical trials, one cross-sectional chart review, and 2 experimental animal studies did not. Thus, the available evidence does not strongly support a clinically significant interaction between alcohol and oral MTZ, calling into question the need for strict alcohol abstinence during treatment."
Journal • Cardiovascular
November 30, 2025
Topical versus oral metronidazole for post-haemorrhoidectomy pain: A systematic review and meta-analysis of randomized controlled trials.
(PubMed, Colorectal Dis)
- "Topical and oral metronidazole showed similar short-term analgesic efficacy after haemorrhoidectomy."
Clinical • Journal • Retrospective data • Review • Pain
November 27, 2025
Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: Gateway Pharmaceutical LLC
New P1 trial • Infectious Disease
November 26, 2025
Title of the Protocol: Combined Use of Vaginal Clindamycin Cream and Oral Metronidazole Versus Oral Metronidazole
(clinicaltrials.gov)
- P=N/A | N=100 | Completed | Sponsor: Ain Shams Maternity Hospital
New trial • Vaginitis
November 19, 2025
Metronidazole as Preoperative Therapy in CRC / FusoMetro-001
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: Oncology Institute of Southern Switzerland | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026
Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor
November 19, 2025
Vaginitis: Diagnosis and Treatment.
(PubMed, Am Fam Physician)
- "Bacterial vaginosis is treated with oral or intravaginal metronidazole or intravaginal clindamycin...Trichomoniasis is treated with oral metronidazole or tinidazole. When treating trichomoniasis, testing for reinfection, as well as other sexually transmitted infections, is recommended. Treatments for noninfectious vaginitis include vaginal lubricants and moisturizers, topical hormones, and topical steroids, depending on the cause."
Journal • Review • Candidiasis • Dermatology • Gynecology • Infectious Disease • Inflammation • Pruritus • Vaginitis
November 18, 2025
REaCT-NSQIP: Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery
(clinicaltrials.gov)
- P4 | N=630 | Recruiting | Sponsor: Ottawa Hospital Research Institute | Trial completion date: Dec 2026 ➔ Jul 2026 | Trial primary completion date: Sep 2025 ➔ May 2026
Trial completion date • Trial primary completion date
November 11, 2025
Male Partner Treatment and the Potential Sexual Transmission of Bacterial Vaginosis: Considerations for Patient Counseling and Clinical Application in the United States.
(PubMed, Am J Obstet Gynecol)
- "However, for the first time, an open-label, randomized controlled trial in Australia showed a decrease in BV recurrences in women whose male partners were treated with a combination of oral metronidazole and topical clindamycin cream over 12 weeks. This has resulted in increasing questions from patients regarding both MPT and the sexual transmissibility of BV. Here, we review evidence regarding the sexual transmission of BV, discuss complexities with potential implementation of MPT, and provide a framework from which to counsel patients."
Journal • Gynecology • Vaginitis
1 to 25
Of
507
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21